Purpose
To develop and validate a web-based reading test for normal and low vision patients.
Methods
This is a prospective, comparative trial. The web-based Democritus Digital Acuity Reading Test (wDDART) was developed. wDDART introduces a series of advanced characteristics (advanced text calibration, computer-vision-based estimation of patient’s distance, and automatic calculation of patient’s reading times) that facilitate the overall examination procedure. wDDART’s reading parameters [reading acuity (RA), maximum reading speed (MRS), critical print size (CPS) and reading accessibility index (ACC)] were compared to the corresponding ones of its conventional Windows-based reading test (DDART) in a sample of normal and low vision participants. wDDART’s test–retest reliability for all reading parameters was evaluated in a 15-day time-window.
Results
One hundred patients (normal vision group-NVG: 70; low vision group-LVG: 30 patients) responded to DDART and wDDART. Non-significant differences between the two reading tests were found for all parameters in NVG and LVG. Intraclass correlation coefficients (ICCs) between the two tests demonstrated good or excellent correlation for RA, MRS, ACC and moderate correlation for CPS. Test–retest reliability was excellent for RA and ACC, while ICCs were 0.715–0.895 for MRS and CPS.
Conclusion
The wDDART demonstrated sufficient validity and repeatability making it suitable for clinical and research settings.
Clinicaltrials.gov Identifier
NCT04618224.
DDART is a valid web-based visual acuity test not only for the near and intermediate vision assessment but also for distance vision and can provide reliable measurements in telemedical settings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.